Erratum: US biodefense contracts continue to lure biotechs

Article metrics

Nat. Biotechnol. 28, 187–188 (2010); published online 8 March 2010; corrected after print DD Month 9 July 2010

In the version of this article initially published, in Table 1, the Emergent BioSolutions' anthrax countermeasures in development listed AV-7909 as being in phase 2 under a $447.6 million BARDA contract; AV-7909 is in phase 1 and the BARDA contract is for $29.7 million. AIGIV is in phase 1/3, not phase 1/2. Finally, a third product was omitted; anthrax monoclonal is in preclinical testing under a $24 million BARDA contract. The $447.6 million BARDA contract was for procurement and product enhancements on BioThrax. Also, on p.188, column 2, line 7, the vaccine requires five injections, not six as originally stated. The error has been corrected in the HTML and PDF versions of the article.

Additional information

The online version of the original article can be found at 10.1038/nbt0310-187

Rights and permissions

Reprints and Permissions

About this article